Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

In July 2017, the journal issued an editorial expression of concern (https://doi.org/10.15252/emmm.201707895) to alert readers that the data in Figs 4 and 5 needed further analysis and verification. Researchers at Roche have since confirmed in an independent study based on independently obtained data that the conclusions from these figures are valid (Foxton et al, 2019). The journal analysed source data for Figs 1, 4, 5, 6 and 9 of Regula et al, 2016; inconsistencies and omissions between the published data and the source data are corrected as follows. Figures 4 and 5 contain panels that derive from different mice but show highly similar whole-mount retinae preparations. David Shima shared available source data related to these figures with the journal. The editors of the journal were not able to find matches for the majority of the panels displayed in the published figures. There was no institutional investigation of this matter. As a result, Figs 4 and 5A–G are herewith retracted and marked accordingly in the published article. Additionally, the following figures are corrected: